In summary, HMGB1 activates multiple inflammatory factors in TME by activating signaling pathways such as RAGE, TLR4, and PI3K, thereby promoting tumor growth, facilitating cellular invasion and metastatic spread, while concurrently contributing to therapeutic resistance in cancer treatment. Here, TLR4 is linked to cancer.